Annual Revenue
$3.83 B
+$174.83 M+4.78%
31 December 2023
Summary:
Jazz Pharmaceuticals annual revenue is currently $3.83 billion, with the most recent change of +$174.83 million (+4.78%) on 31 December 2023. During the last 3 years, it has risen by +$1.47 billion (+62.22%). JAZZ annual revenue is now at all-time high.JAZZ Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$1.05 B
+$31.14 M+3.04%
30 September 2024
Summary:
Jazz Pharmaceuticals quarterly revenue is currently $1.05 billion, with the most recent change of +$31.14 million (+3.04%) on 30 September 2024. Over the past year, it has increased by +$82.83 million (+8.52%). JAZZ quarterly revenue is now at all-time high.JAZZ Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$3.99 B
+$82.83 M+2.12%
30 September 2024
Summary:
Jazz Pharmaceuticals TTM revenue is currently $3.99 billion, with the most recent change of +$82.83 million (+2.12%) on 30 September 2024. Over the past year, it has increased by +$198.32 million (+5.23%). JAZZ TTM revenue is now at all-time high.JAZZ TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.8% | +8.5% | +5.2% |
| 3 y3 years | +62.2% | +25.9% | +39.5% |
| 5 y5 years | +102.8% | +96.2% | +94.2% |
JAZZ Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +62.2% | at high | +29.6% | at high | +39.5% |
| 5 y | 5 years | at high | +102.8% | at high | +97.3% | at high | +94.2% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
Jazz Pharmaceuticals Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.05 B(+3.0%) | $3.99 B(+2.1%) |
| June 2024 | - | $1.02 B(+13.5%) | $3.91 B(+1.7%) |
| Mar 2024 | - | $901.98 M(-10.9%) | $3.84 B(+0.2%) |
| Dec 2023 | $3.83 B(+4.8%) | $1.01 B(+4.1%) | $3.83 B(+1.0%) |
| Sept 2023 | - | $972.14 M(+1.5%) | $3.79 B(+0.8%) |
| June 2023 | - | $957.32 M(+7.2%) | $3.76 B(+0.7%) |
| Mar 2023 | - | $892.81 M(-8.2%) | $3.74 B(+2.2%) |
| Dec 2022 | $3.66 B(+18.3%) | $972.12 M(+3.3%) | $3.66 B(+2.1%) |
| Sept 2022 | - | $940.65 M(+0.8%) | $3.58 B(+2.9%) |
| June 2022 | - | $932.88 M(+14.6%) | $3.48 B(+5.5%) |
| Mar 2022 | - | $813.72 M(-9.3%) | $3.30 B(+6.7%) |
| Dec 2021 | $3.09 B(+30.9%) | $896.73 M(+7.0%) | $3.09 B(+8.1%) |
| Sept 2021 | - | $838.12 M(+11.5%) | $2.86 B(+9.0%) |
| June 2021 | - | $751.81 M(+23.7%) | $2.63 B(+7.8%) |
| Mar 2021 | - | $607.58 M(-8.7%) | $2.44 B(+3.1%) |
| Dec 2020 | $2.36 B(+9.3%) | $665.52 M(+10.8%) | $2.36 B(+3.7%) |
| Sept 2020 | - | $600.89 M(+6.8%) | $2.28 B(+2.9%) |
| June 2020 | - | $562.44 M(+5.2%) | $2.22 B(+1.3%) |
| Mar 2020 | - | $534.73 M(-8.1%) | $2.19 B(+1.2%) |
| Dec 2019 | $2.16 B(+14.3%) | $581.74 M(+8.2%) | $2.16 B(+5.1%) |
| Sept 2019 | - | $537.70 M(+0.7%) | $2.06 B(+3.4%) |
| June 2019 | - | $534.13 M(+5.1%) | $1.99 B(+1.7%) |
| Mar 2019 | - | $508.19 M(+6.7%) | $1.95 B(+3.4%) |
| Dec 2018 | $1.89 B(+16.8%) | $476.46 M(+1.5%) | $1.89 B(+2.2%) |
| Sept 2018 | - | $469.37 M(-6.2%) | $1.85 B(+3.2%) |
| June 2018 | - | $500.48 M(+12.6%) | $1.79 B(+6.3%) |
| Mar 2018 | - | $444.61 M(+1.9%) | $1.69 B(+4.2%) |
| Dec 2017 | $1.62 B(+8.8%) | $436.40 M(+6.0%) | $1.62 B(+2.5%) |
| Sept 2017 | - | $411.86 M(+4.4%) | $1.58 B(+2.4%) |
| June 2017 | - | $394.39 M(+4.9%) | $1.54 B(+0.9%) |
| Mar 2017 | - | $376.05 M(-5.2%) | $1.53 B(+2.7%) |
| Dec 2016 | $1.49 B(+12.3%) | $396.62 M(+6.0%) | $1.49 B(+3.9%) |
| Sept 2016 | - | $374.18 M(-1.8%) | $1.43 B(+2.4%) |
| June 2016 | - | $381.16 M(+13.4%) | $1.40 B(+3.5%) |
| Mar 2016 | - | $336.01 M(-1.4%) | $1.35 B(+2.0%) |
| Dec 2015 | $1.32 B(+13.0%) | $340.88 M(+0.0%) | $1.32 B(+1.0%) |
| Sept 2015 | - | $340.87 M(+2.1%) | $1.31 B(+2.7%) |
| June 2015 | - | $333.75 M(+7.9%) | $1.28 B(+3.4%) |
| Mar 2015 | - | $309.30 M(-5.7%) | $1.24 B(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | $1.17 B(+34.4%) | $328.14 M(+7.0%) | $1.17 B(+8.5%) |
| Sept 2014 | - | $306.58 M(+5.3%) | $1.08 B(+7.4%) |
| June 2014 | - | $291.23 M(+17.9%) | $1.01 B(+9.0%) |
| Mar 2014 | - | $246.92 M(+4.7%) | $923.11 M(+5.8%) |
| Dec 2013 | $872.42 M(+48.9%) | $235.77 M(+1.6%) | $872.42 M(+6.3%) |
| Sept 2013 | - | $232.16 M(+11.5%) | $820.35 M(+7.4%) |
| June 2013 | - | $208.25 M(+6.1%) | $763.71 M(+12.4%) |
| Mar 2013 | - | $196.24 M(+6.8%) | $679.69 M(+16.0%) |
| Dec 2012 | $585.98 M(+115.2%) | $183.70 M(+4.7%) | $585.98 M(+20.6%) |
| Sept 2012 | - | $175.51 M(+41.3%) | $485.81 M(+26.6%) |
| June 2012 | - | $124.23 M(+21.2%) | $383.59 M(+18.4%) |
| Mar 2012 | - | $102.53 M(+22.7%) | $323.93 M(+19.0%) |
| Dec 2011 | $272.28 M(+56.7%) | $83.54 M(+14.0%) | $272.28 M(+12.5%) |
| Sept 2011 | - | $73.29 M(+13.5%) | $242.11 M(+13.4%) |
| June 2011 | - | $64.57 M(+26.9%) | $213.57 M(+12.7%) |
| Mar 2011 | - | $50.88 M(-4.7%) | $189.49 M(+9.0%) |
| Dec 2010 | $173.78 M(+35.3%) | $53.37 M(+19.3%) | $173.78 M(+9.5%) |
| Sept 2010 | - | $44.75 M(+10.5%) | $158.70 M(+9.6%) |
| June 2010 | - | $40.49 M(+15.1%) | $144.75 M(+2.3%) |
| Mar 2010 | - | $35.17 M(-8.1%) | $141.55 M(+10.2%) |
| Dec 2009 | $128.45 M(+90.3%) | $38.28 M(+24.3%) | $128.45 M(+17.0%) |
| Sept 2009 | - | $30.81 M(-17.4%) | $109.76 M(+13.5%) |
| June 2009 | - | $37.28 M(+68.9%) | $96.70 M(+29.0%) |
| Mar 2009 | - | $22.08 M(+12.7%) | $74.96 M(+11.0%) |
| Dec 2008 | $67.51 M(+3.4%) | $19.59 M(+10.4%) | $67.51 M(+6.5%) |
| Sept 2008 | - | $17.75 M(+14.2%) | $63.40 M(-5.6%) |
| June 2008 | - | $15.54 M(+6.2%) | $67.12 M(+1.9%) |
| Mar 2008 | - | $14.63 M(-5.4%) | $65.85 M(+0.8%) |
| Dec 2007 | $65.30 M(+45.6%) | $15.48 M(-27.9%) | $65.30 M(+6.2%) |
| Sept 2007 | - | $21.47 M(+50.5%) | $61.50 M(+19.0%) |
| June 2007 | - | $14.26 M(+1.2%) | $51.70 M(+5.3%) |
| Mar 2007 | - | $14.09 M(+20.7%) | $49.11 M(+9.5%) |
| Dec 2006 | $44.86 M(+109.2%) | $11.67 M(0.0%) | $44.86 M(+16.4%) |
| Sept 2006 | - | $11.67 M(0.0%) | $38.54 M(+19.6%) |
| June 2006 | - | $11.67 M(+18.7%) | $32.23 M(+24.4%) |
| Mar 2006 | - | $9.84 M(+83.5%) | $25.92 M(+20.9%) |
| Dec 2005 | $21.44 M | $5.36 M(-0.0%) | $21.44 M(+33.3%) |
| Sept 2005 | - | $5.36 M(0.0%) | $16.08 M(+50.0%) |
| June 2005 | - | $5.36 M(0.0%) | $10.72 M(+100.0%) |
| Mar 2005 | - | $5.36 M | $5.36 M |
FAQ
- What is Jazz Pharmaceuticals annual revenue?
- What is the all time high annual revenue for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual revenue year-on-year change?
- What is Jazz Pharmaceuticals quarterly revenue?
- What is the all time high quarterly revenue for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly revenue year-on-year change?
- What is Jazz Pharmaceuticals TTM revenue?
- What is the all time high TTM revenue for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals TTM revenue year-on-year change?
What is Jazz Pharmaceuticals annual revenue?
The current annual revenue of JAZZ is $3.83 B
What is the all time high annual revenue for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual revenue is $3.83 B
What is Jazz Pharmaceuticals annual revenue year-on-year change?
Over the past year, JAZZ annual revenue has changed by +$174.83 M (+4.78%)
What is Jazz Pharmaceuticals quarterly revenue?
The current quarterly revenue of JAZZ is $1.05 B
What is the all time high quarterly revenue for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly revenue is $1.05 B
What is Jazz Pharmaceuticals quarterly revenue year-on-year change?
Over the past year, JAZZ quarterly revenue has changed by +$82.83 M (+8.52%)
What is Jazz Pharmaceuticals TTM revenue?
The current TTM revenue of JAZZ is $3.99 B
What is the all time high TTM revenue for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high TTM revenue is $3.99 B
What is Jazz Pharmaceuticals TTM revenue year-on-year change?
Over the past year, JAZZ TTM revenue has changed by +$198.32 M (+5.23%)